UTRS · Minerva Surgical Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.96M | $13.39M | - | $12.59M | $14.11M | $10.94M | - | $12.51M |
| Cost of Revenue | $5.75M | $5.99M | - | $5.78M | $5.38M | $5.52M | - | $5.72M |
| Gross Profit | $6.22M | $7.40M | - | $6.81M | $7.64M | $6.83M | - | $6.55M |
| R&D | $1.41M | $1.48M | - | $1.46M | $1.67M | $1.25M | - | $1.37M |
| SG&A | $4.19M | $4.22M | - | $6.14M | $10.13M | $4.99M | - | $1.80M |
| Total Operating Expenses | $12.31M | $15.06M | - | $17.32M | $20.30M | $15.71M | - | $13.27M |
| D&A | $500.0K | $500.0K | - | $600.0K | $600.0K | $600.0K | - | $500.0K |
| Operating Income | ($6.10M) | ($7.66M) | - | ($10.51M) | ($11.56M) | ($10.30M) | - | ($3.17M) |
| Interest Expense | $1.17M | $1.13M | - | $861.0K | $703.0K | $632.0K | - | $3.29M |
| Income Tax | $3.0K | $39.0K | - | $0 | $0 | - | - | $0 |
| Net Income | ($7.18M) | ($8.68M) | - | ($11.33M) | ($5.61M) | ($10.93M) | - | ($3.23M) |
| EPS - Basic | ($0.81) | ($1.00) | - | ($8.00) | ($109.60) | - | - | - |
| EPS - Diluted | ($0.81) | ($1.00) | - | ($23.00) | ($109.60) | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.13M | $15.71M | $6.94M | $15.11M | $22.39M | $27.90M | $40.61M | $6.13M |
| Accounts Receivable | $7.57M | $7.95M | $7.24M | $6.79M | $7.02M | $7.15M | $7.29M | $6.76M |
| Inventory | $18.18M | $17.88M | $16.85M | $17.00M | $16.93M | $16.00M | $15.68M | $14.96M |
| Accounts Payable | $3.04M | $3.82M | $2.80M | $2.82M | $3.27M | $3.06M | $3.63M | $3.51M |
| Current Assets | $40.00M | $46.08M | $36.12M | $49.20M | $57.28M | $61.48M | $75.00M | $39.87M |
| Total Assets | $72.78M | $79.30M | $68.90M | $83.80M | $93.96M | $100.50M | $115.09M | $81.19M |
| Current Liabilities | $21.25M | $18.08M | $14.28M | $23.00M | $23.90M | $26.47M | $22.81M | $66.27M |
| Long-term Debt | $27.89M | $31.07M | $37.44M | $39.27M | $39.21M | $39.15M | $39.09M | $18.22M |
| Total Liabilities | $52.53M | $52.72M | $51.72M | $62.27M | $63.11M | $65.76M | $70.99M | $205.32M |
| Stockholders' Equity | $20.25M | $26.59M | $17.18M | $21.54M | $30.85M | $34.74M | $44.10M | ($208.48M) |
| Retained Earnings | ($310.72M) | ($303.54M) | ($283.67M) | ($277.42M) | ($266.09M) | ($260.48M) | ($249.56M) | ($260.36M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.39M) | - | - | - | - | ($2.92M) | - | - |
| Investing Cash Flow | ($75.0K) | - | - | - | - | ($401.0K) | - | - |
| Financing Cash Flow | $26.77M | - | - | - | - | $886.0K | - | - |
| CapEx | $75.0K | - | - | - | - | $401.0K | - | - |
| Free Cash Flow | ($8.46M) | - | - | - | - | ($3.32M) | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | 52.0% | 55.3% | - | 54.1% | 54.2% | 62.5% | - | 52.4% |
| Operating margin | -50.9% | -57.2% | - | -83.5% | -81.9% | -94.2% | - | -25.4% |
| EBITDA margin | -46.8% | -53.5% | - | -78.7% | -77.7% | -88.7% | - | -21.4% |
| Net margin | -60.0% | -64.8% | - | -90.0% | -39.8% | -99.9% | - | -25.8% |
| Free cash flow margin | -70.7% | - | - | - | - | -30.4% | - | - |
| FCF / Net income | 1.18 | - | - | - | - | 0.30 | - | - |
| R&D / Revenue | 11.8% | 11.0% | - | 11.6% | 11.9% | 11.5% | - | 10.9% |
| SG&A / Revenue | 35.0% | 31.5% | - | 48.8% | 71.7% | 45.6% | - | 14.4% |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -9.9% | -10.9% | - | -13.5% | -6.0% | -10.9% | - | -4.0% |
| Return on equity | -35.5% | -32.7% | - | -52.6% | -18.2% | -31.4% | - | 1.5% |
| Return on invested capital | -10.0% | -10.5% | - | -13.7% | -13.0% | - | - | - |
| Liquidity | ||||||||
| Current ratio | 1.88 | 2.55 | 2.53 | 2.14 | 2.40 | 2.32 | 3.29 | 0.60 |
| Quick ratio | 1.03 | 1.56 | 1.35 | 1.40 | 1.69 | 1.72 | 2.60 | 0.38 |
| Cash ratio | 0.52 | 0.87 | 0.49 | 0.66 | 0.94 | 1.05 | 1.78 | 0.09 |
| Leverage | ||||||||
| Debt / Equity | 1.38 | 1.17 | 2.18 | 1.82 | 1.27 | 1.13 | 0.89 | -0.09 |
| Debt / Assets | 0.38 | 0.39 | 0.54 | 0.47 | 0.42 | 0.39 | 0.34 | 0.22 |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | -5.2x | -6.8x | - | -12.2x | -16.4x | -16.3x | - | -1.0x |
| Equity multiplier | 3.59 | 2.98 | 4.01 | 3.89 | 3.05 | 2.89 | 2.61 | -0.39 |
| Liabilities / Assets | 0.72 | 0.66 | 0.75 | 0.74 | 0.67 | 0.65 | 0.62 | 2.53 |
| Efficiency | ||||||||
| Asset turnover | 0.16 | 0.17 | - | 0.15 | 0.15 | 0.11 | - | 0.15 |
| Inventory turnover | 0.32 | 0.33 | - | 0.34 | 0.32 | 0.35 | - | 0.38 |
| Days sales outstanding | 231d | 217d | - | 197d | 181d | 239d | - | 197d |
| Days inventory outstanding | 1155d | 1090d | - | 1075d | 1148d | 1058d | - | 954d |
| Days payable outstanding | 193d | 233d | - | 178d | 222d | 202d | - | 224d |
| Cash conversion cycle | 1193d | 1074d | - | 1093d | 1108d | 1094d | - | 927d |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | 0.2x | - | - | - | - | - | - | - |
| P / S | 0.4x | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | -4.9% | -5.1% | - | 0.7% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -8.7% | -3.2% | - | 3.9% | - | - | - | - |
| Operating income growth (YoY) | 42.0% | 33.8% | - | -231.4% | - | - | - | - |
| Net income growth (YoY) | 36.6% | -54.7% | - | -251.3% | - | - | - | - |
| EPS growth (YoY) | 96.5% | 99.1% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -6.0% | -13.8% | -61.0% | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$100.0K totalWarranty Service$100.0K · 100.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing MINERVA SURGICAL INC against the 5 most active filers in the same SIC group.